Pramipexole
- Generic Name
- Pramipexole
- Brand Names
- Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N3S
- CAS Number
- 104632-26-0
- Unique Ingredient Identifier
- 83619PEU5T
- Background
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients , leading to increased difficulty in performing activities of daily living due to symptoms that progress over time . The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016 . This increase may be attributed to an aging population along with other contributing factors .
In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) . RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs .
- Indication
This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1464
- Registration Number
- NCT02231294
Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
- Conditions
- AnxietyDepression
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 160
- Registration Number
- NCT02220309
- Locations
- 🇺🇸
Gronowski Center-5150 El Camino Real, Los Altos, California, United States
🇺🇸VAPAHCS/Palo Alto MIRECC-3801 Miranda Avenue, Palo Alto, California, United States
🇺🇸Stanford University Department of Psychiatry, Stanford, California, United States
Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 150
- Registration Number
- NCT02177357
Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 315
- Registration Number
- NCT02172573
Imaging Dopamine Release in Depression
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 52
- Registration Number
- NCT02033369
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Mauro Manconi
- Target Recruit Count
- 20
- Registration Number
- NCT02025608
- Locations
- 🇨🇭
Department of Neurology, Inselspital, Bern, Switzerland
🇨🇭Neurocenter of Southern Switzerland, Lugano, Ticino, Switzerland
Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 121
- Registration Number
- NCT01673724
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
Pramipexole as a Treatment for Cocaine Dependence
- Conditions
- Cocaine AbuseCocaine AddictionCocaine DependenceSubstance Abuse
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01651377
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 615
- Registration Number
- NCT01525641
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site 4, Muroran,Hokkaido, Japan
🇯🇵Boehringer Ingelheim Investigational Site 52, Nanao,Ishikawa, Japan
🇯🇵Boehringer Ingelheim Investigational Site 40, Chuo,Tokyo, Japan
Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01515774
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.